# Perspective Therapeutics Inc. (CATX)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $218M  
**Price:** $2.95 (-1.67%)

> Perspective Therapeutics Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative therapeutics and technologies to treat various diseases, primarily within the oncology sector. Its primary function is to advance research that can lead to practical cancer treatment solutions, potentially impacting patient care significantly. The company engages in developing novel targeted therapies, often collaborating with leading research institutions and utilizing cutting-edge scientific techniques. Perspective Therapeutics Inc. plays a critical role in the healthcare market by addressing unmet medical needs and contributing to the growing demand for personalized medicine approaches. The work undertaken by the company holds substantial importance for the biotech and pharmaceutical industries as it seeks to improve therapeutic outcomes and enhance medical capabilities in combating cancer and other serious illnesses. The company's initiatives not only underscore the importance of biotechnology in advancing healthcare solutions but also highlight the ongoing evolution within the medical research landscape.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | — | — | -$114M | -$103M | $-1.40 |
| 2024 | — | — | -$67M | -$79M | $-1.23 |
| 2023 | — | — | -$41M | -$47M | $-1.70 |
| 2022 | $11M | $5M | -$7M | -$7M | $-0.50 |
| 2021 | $10M | $5M | -$3M | -$3M | $-0.30 |
| 2020 | $10M | $5M | -$3M | -$3M | $-0.50 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $267M | $60M | $207M | $31M | $3M |
| 2024 | $341M | $50M | $291M | $62M | $3M |
| 2023 | $98M | $23M | $75M | $9M | $2M |
| 2022 | $64M | $3M | $61M | $56M | $256,000 |
| 2021 | $70M | $3M | $67M | $64M | $524,000 |
| 2020 | $9M | $3M | $6M | $2M | $769,000 |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$93M | -$13M | -$95M |
| 2024 | -$43M | -$54M | -$73M |
| 2023 | -$39M | -$1M | -$38M |
| 2022 | -$8M | -$266,000 | -$8M |
| 2021 | -$3M | -$380,000 | -$3M |
| 2020 | -$4M | -$273,000 | -$4M |

Source: [CompaniesByCap](https://companiesbycap.com/company/CATX)